Provided by Tiger Trade Technology Pte. Ltd.

Gain Therapeutics, Inc.

1.91
-0.0950-4.75%
Post-market: 1.980.0750+3.94%16:16 EDT
Volume:382.85K
Turnover:754.13K
Market Cap:83.14M
PE:-3.74
High:2.05
Open:2.00
Low:1.90
Close:2.00
52wk High:4.34
52wk Low:1.53
Shares:43.64M
Float Shares:42.34M
Volume Ratio:1.18
T/O Rate:0.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5092
EPS(LYR):-0.6115
ROE:-268.30%
ROA:-95.51%
PB:7.36
PE(LYR):-3.12

Loading ...

Gain Therapeutics reports stable MDS-UPDRS scores at Day 150 in Phase 1b trial of Parkinson’s drug GT-02287

Reuters
·
May 26

Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026

GlobeNewswire
·
May 26

Gain Therapeutics price target lowered to $8 from $10 at Roth Capital

TIPRANKS
·
May 13

Gain Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

Gain Therapeutics Q1 loss per share narrows

Reuters
·
May 11

Gain Therapeutics Q1 EPS $(0.13) Beats $(0.14) Estimate

Benzinga Earnings
·
May 11

Press Release: Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update

Dow Jones
·
May 11

Gain Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview

Reuters
·
May 08

Gain Therapeutics announces annual shareholder meeting

Reuters
·
Apr 29

Gain Therapeutics to give oral presentation at International GBA1 Meeting 2026

Reuters
·
Apr 24

Gain Therapeutics Announces Oral Presentation at 3Rd International Gba1 Meeting 2026

THOMSON REUTERS
·
Apr 24

Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026

GlobeNewswire
·
Apr 24

Gain Therapeutics management to meet with Maxim

TIPRANKS
·
Apr 18

Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Neumora Therapeutics, Inc. (NMRA) and Gain Therapeutics (GANX)

TIPRANKS
·
Mar 31

Reiterating Buy on Gain Therapeutics: Promising GT-02287 Parkinson’s Data and Diversified GCase Pipeline Support $8 Target

TIPRANKS
·
Mar 30

Gain Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 26

Gain Therapeutics Q4 EPS $(0.11) Beats $(0.17) Estimate.

Benzinga Earnings
·
Mar 26

Gain Therapeutics FY2025 net loss per share narrows 31.46% to $0.61; cash, cash equivalents and marketable securities climb more than doubled to $20.8 million

Reuters
·
Mar 26

Gain Therapeutics Inc - 2025 Net Loss $20.2 Mln, or $0.61 per Share

THOMSON REUTERS
·
Mar 26

Gain Therapeutics Inc - Clearance of Ind Submission to FDA for Phase 2 of GT-02287 Expected in 2Q26

THOMSON REUTERS
·
Mar 26